Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended June 27, 2009 (First Quarter of Fiscal Year 2010)
Business Overview: Haemonetics designs, manufactures, and markets automated blood processing systems, including devices, single-use disposables, and software solutions for blood and plasma collection, processing, and management.
Key Financial Metrics
| Metric | Q1 FY2010 (Jun 27, 2009) | Q1 FY2009 (Jun 28, 2008) |
|---|---|---|
| Net Revenues | $154,087,000 | $144,116,000 |
| Gross Profit | $82,943,000 | $73,037,000 |
| Gross Margin | 53.8% | 50.7% |
| Operating Income | $26,327,000 | $19,334,000 |
| Operating Margin | 17.1% | 13.4% |
| Net Income | $18,073,000 | $14,341,000 |
| Diluted EPS | $0.69 | $0.54 |
| Cash and Equivalents | $173,822,000 | $120,287,000 |
| Working Capital | $292,102,000 | $289,530,000 |
| Total Debt (Current + Long-term) | $22,360,000 | $6,038,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 6.9% year-over-year. Organic growth was 6.2%, driven primarily by a 25.6% increase in Plasma disposables revenue and a 16.5% increase in Software solutions revenue. Foreign exchange contributed a 0.7% increase.
- Profitability: Operating income surged 36.2% to $26.3 million. This was largely driven by a favorable foreign exchange impact (37.7% increase). Excluding currency effects, operating income decreased slightly (1.5%) due to higher operating expenses.
- Expense Increases: Operating expenses rose 5.4% to $56.6 million. Key drivers included increased R&D spending (16.0% increase), costs associated with recent acquisitions (Neoteric and Altivation), and expenses related to the ERP Phase II go-live.
- Product Mix: While Plasma disposables grew significantly, Blood Bank disposables declined 3.0% (impacted by currency devaluation in South Korea and share loss in Japan), and Equipment & Other revenues dropped 14.6% due to reduced capital spending by hospital customers.
Guidance, Outlook, and Risks
- Outlook: Management anticipates plasma disposable revenue growth will continue to outpace collection market growth in the near term, moderating to a low-to-mid double-digit rate over the next 18 months. The company expects work on the next-generation Donor apheresis platform to resume in Fiscal Year 2010.
- Acquisitions: The company acquired Neoteric (L'Attitude Medical Systems) for $6.7 million plus contingent consideration to broaden blood management solutions. Results are included in the quarter.
- Legal Proceedings: In a patent infringement lawsuit against Fenwal Inc., a jury awarded Haemonetics $15.7 million in damages. The court ruled Fenwal must stop selling ALYX consumables by December 1, 2010, and pay a 10% royalty on sales until then. This ruling is subject to appeal.
- Risks: Significant exposure to foreign exchange rates (51% of sales are international). Risks include economic conditions affecting hospital capital spending, competitive pricing, and regulatory changes. The company utilizes forward contracts to hedge currency exposure.
- Liquidity: The Board approved a $40 million share repurchase program in May 2009; no shares had been repurchased as of June 27, 2009. The company maintains a strong net cash position of approximately $151.5 million.
Investor Verification Checklist
- Plasma Market Dynamics: Verify the sustainability of the 25.6% growth in plasma disposables and the management's projection of moderating growth rates.
- Foreign Exchange Impact: Assess the sensitivity of future earnings to fluctuations in the Euro and Japanese Yen, given that 51% of revenue is international.
- Legal Settlement: Monitor the status of the Fenwal patent litigation appeal and the potential for royalty income or injunction enforcement.
- Acquisition Integration: Review the financial performance and integration progress of the Neoteric and Altivation acquisitions.
- Capital Expenditures: Evaluate the impact of the ERP implementation and increased CapEx ($21.2 million in the quarter) on future cash flows.